Previous Close | 3.69 |
Open | 3.75 |
Bid | 3.77 x 400 |
Ask | 3.79 x 800 |
Day's Range | 3.54 - 3.80 |
52 Week Range | 1.74 - 6.68 |
Volume | 3,225,404 |
Avg. Volume | 7,176,876 |
Market Cap | 608.879M |
Beta | 2.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.18 |
Earnings Date | May 4, 2017 - May 8, 2017 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.50 |
Matthew Cheslock joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.
Geron's experimental blood cancer drug remains a top priority for the pharma behemoth Johnson & Johnson.
MENLO PARK, Calif., April 17, 2018-- Geron Corporation will hold its 2018 Annual Meeting of Stockholders, on Tuesday, May 15, 2018, at 4:00 p.m. PDT.. Geron’ s stockholders are invited to attend the Annual ...
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Rigel shares were popping on Thursday but unfortunately it was due to a mistake. The company corrected the mistake after-hours and announced that there had ...
The small-cap oncology biotech's stock is likely to see big movement next week.
Chip Scarlett took the reins as CEO of Geron Corporation’s (NASDAQ:GERN) and grew market cap to US$531.76M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
Geron's shares are on the move again today. Here's why.
Geron's risk-to-reward ratio might be too juicy to pass up.
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Geron Corporation ("Geron" or the "Company") ...
Glancy Prongay & Murray LLP announces an investigation on behalf of Geron Corporation investors concerning the Company and its officers’ possible violations of federal securities laws.
Levi & Korsinsky announces it has commenced an investigation of Geron Corporation concerning possible violations of federal securities laws.
Geron's stock can't seem to find a bottom.
The short argument against Geron doesn't add up. Here's why.
Geron’s future hinges on an uncertainty and AbbVie’s teetering following disappointing news. Do these stocks deserve a place in your portfolio?
LOS ANGELES, CA / ACCESSWIRE / March 29, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Geron Corporation ...
These highfliers could could climb higher. Here's what needs to happen.
Competitors could soon threaten Jakafi's sales.